- Home
- ANVS vs TLSI Comparison
ANVS vs TLSI Comparison
Compare ANVS & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- TLSI
- Stock Information
- Founded
- ANVS 2008
- TLSI 2010
- Country
- ANVS United States
- TLSI United States
- Employees
- ANVS N/A
- TLSI N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- ANVS Health Care
- TLSI Health Care
- Exchange
- ANVS Nasdaq
- TLSI Nasdaq
- Market Cap
- ANVS 110.4M
- TLSI 124.9M
- IPO Year
- ANVS 2020
- TLSI N/A
- Fundamental
- Price
- ANVS $6.85
- TLSI $3.93
- Analyst Decision
- ANVS Strong Buy
- TLSI Strong Buy
- Analyst Count
- ANVS 6
- TLSI 5
- Target Price
- ANVS $29.67
- TLSI $12.10
- AVG Volume (30 Days)
- ANVS 261.0K
- TLSI 25.0K
- Earning Date
- ANVS 11-08-2024
- TLSI 11-14-2024
- Dividend Yield
- ANVS N/A
- TLSI N/A
- EPS Growth
- ANVS N/A
- TLSI N/A
- EPS
- ANVS N/A
- TLSI N/A
- Revenue
- ANVS N/A
- TLSI $26,892,000.00
- Revenue This Year
- ANVS N/A
- TLSI $61.76
- Revenue Next Year
- ANVS N/A
- TLSI $47.30
- P/E Ratio
- ANVS N/A
- TLSI N/A
- Revenue Growth
- ANVS N/A
- TLSI 67.92
- 52 Week Low
- ANVS $4.53
- TLSI $3.32
- 52 Week High
- ANVS $22.49
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- ANVS 30.84
- TLSI 39.39
- Support Level
- ANVS $7.30
- TLSI $3.74
- Resistance Level
- ANVS $8.93
- TLSI $4.66
- Average True Range (ATR)
- ANVS 0.56
- TLSI 0.29
- MACD
- ANVS -0.26
- TLSI 0.02
- Stochastic Oscillator
- ANVS 4.89
- TLSI 20.77
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.